3 Drugs Stocks Moving The Industry Upward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 129 points (-0.8%) at 16,373 as of Friday, April 25, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 935 issues advancing vs. 2,039 declining with 150 unchanged.

The Drugs industry currently sits down 2.3% versus the S&P 500, which is down 0.6%. Top gainers within the industry include Prestige Brands Holdings ( PBH), up 17.5%, and AbbVie ( ABBV), up 1.2%. On the negative front, top decliners within the industry include Cytokinetics ( CYTK), down 61.5%, Regeneron Pharmaceuticals ( REGN), down 2.5%, Actavis ( ACT), down 1.8%, Teva Pharmaceutical Industries ( TEVA), down 1.7% and Alexion Pharmaceuticals ( ALXN), down 1.1%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Mylan ( MYL) is one of the companies pushing the Drugs industry higher today. As of noon trading, Mylan is up $1.46 (2.9%) to $51.81 on heavy volume. Thus far, 8.5 million shares of Mylan exchanged hands as compared to its average daily volume of 5.8 million shares. The stock has ranged in price between $49.06-$53.57 after having opened the day at $49.86 as compared to the previous trading day's close of $50.35.

Mylan Inc., a pharmaceutical company, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. It operates in two segments, Generics and Specialty. Mylan has a market cap of $18.7 billion and is part of the health care sector. Shares are up 16.0% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts who rate Mylan a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Mylan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, growth in earnings per share, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Mylan Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

FDA Official Calls for Ending Codeine Use in Kids Cough Products

Will Allergan's Deal With Tribe Hold Up?

Trading Mylan: Look Out for This Key Level

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids